In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Serum modified high density lipoprotein levels assessed by a novel assay was associated with coronary artery calcification in an apparently healthy population

Session HDL cholesterol - A moving target

Speaker Tomonori Okamura

Congress : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Lipids
  • Session type : Advances in Science
  • FP Number : 51

Authors : T Okamura (Tokyo,JP), A Kakino (Matsumoto,JP), K Miura (Otsu,JP), A Fujiyoshi (Otsu,JP), A Kadota (Otsu,JP), Y Fujita (Matsumoto,JP), M Zaid (Otsu,JP), Y Usami (Matsumoto,JP), T Hisamastu (Izumo,JP), S Horiuchi (Matsumoto,JP), A Kunimura (Otsu,JP), D Sugiyama (Tokyo,JP), K Kondo (Otsu,JP), T Sawamura (Matsumoto,JP), H Ueshima (Otsu,JP)

Authors:
T. Okamura1 , A. Kakino2 , K. Miura3 , A. Fujiyoshi3 , A. Kadota3 , Y. Fujita2 , M. Zaid3 , Y. Usami2 , T. Hisamastu4 , S. Horiuchi2 , A. Kunimura3 , D. Sugiyama1 , K. Kondo3 , T. Sawamura2 , H. Ueshima3 , 1Keio University School of Medicine, Preventive Medicine and Public Health - Tokyo - Japan , 2Shinshu University, Physiology - Matsumoto - Japan , 3Shiga University of Medical Science - Otsu - Japan , 4Shimane University, Faculty of Medicine - Izumo - Japan ,

On behalf: Shiga Epidemiological Study of Subclinical Atherosclerosis Research Group

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 4

Introduction: Previous studies have shown that high density lipoprotein (HDL) cholesterol is protective against coronary artery disease. However, recent studies suggested that the quality or function of HDL was more important than levels of HDL cholesterol. Recently, we have developed a brand-new assay to detect serum modified HDL, which is thought to be a non-functional or atherogenic form of HDL.

Purpose: The relationship between modified HDL and coronary artery calcification (CAC) was examined in apparently healthy Japanese individuals who participated in a cohort study for examination of subclinical atherosclerosis of community dwellers. Participants were randomly selected from one city in the west part of Japan.

Method: Study population consists of 1,009 Japanese men aged 40–79 years without clinical cardiovascular diseases, of which mean age was 64 (Standard Deviation, SD: 10.1). CAC was measured by electron-beam computed tomography (EBCT) or multi-detector-row computed tomography (MDCT). LOX-1 (lectin-like oxidized LDL receptor) is the receptor that mediates modified LDL (low density lipoprotein) activity in vascular endothelial cells; however, some lipoproteins with apolipoprotein A1 (Apo A-1) are also bonded to LOX-1. In the present study, serum LOX-1 ligand containing Apo A-1 was defined as modified HDL. Modified HDL levels were measured by enzyme-linked immunosorbent assays (ELISAs) with recombinant LOX-1 and anti-Apo A-1 antibody. Associations of modified HDL with CAC (>10 Agatston score) were examined using logistic regression with adjustment for confounding factors, including HDL cholesterol.

Results: Mean HDL cholesterol level was 58.5 mg/dl (SD: 16.8) and mean modified HDL cholesterol level was 204 ng/ml (SD: 89.7). Serum modified HDL levels were significantly associated with CAC; age-adjusted OR (odd ratio) for the presence of CAC was 1.29 (95% confidence interval: 95% CI: 1.12–1.48). After further adjustment for hypertension, diabetes, smoking, body mass index, HDL cholesterol, non-HDL cholesterol and lipid lowering medication, the significant association was still observed, of which OR was 1.22 (95% CI: 1.05–1.42). Additional adjustment for high sensitivity C-reactive protein (CRP) also did not alter the results.

Conclusions: Serum modified HDL, i.e., LOX-1 ligand containing Apo A-1, might be a novel biomarker for subclinical atherosclerosis in apparently healthy individuals.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are